BS_NB42PWZN
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 67.8712220762155
- age_years
- 18.342
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.411
- WNT_BETA_CATENIN_SIGNALING+0.408
- E2F_TARGETS+0.290
- NOTCH_SIGNALING+0.250
- DNA_REPAIR+0.216
- UNFOLDED_PROTEIN_RESPONSE+0.166
- MYC_TARGETS_V2+0.137
- HYPOXIA+0.108
- MITOTIC_SPINDLE+0.104
- TGF_BETA_SIGNALING+0.098
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.508
- ALLOGRAFT_REJECTION-0.502
- KRAS_SIGNALING_UP-0.391
- IL6_JAK_STAT3_SIGNALING-0.387
- COMPLEMENT-0.382
- INTERFERON_GAMMA_RESPONSE-0.374
- INFLAMMATORY_RESPONSE-0.367
- PROTEIN_SECRETION-0.297
- IL2_STAT5_SIGNALING-0.278
- FATTY_ACID_METABOLISM-0.276
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NB42PWZN | EPN | Supratentorial EPN | 0.943 |
| 2 | SRR15030862 | — | — | 0.836 |
| 3 | BS_N5DVEJXT | Supratentorial Ependymoma | — | 0.825 |
| 4 | BS_C05FKR8X | Supratentorial Ependymoma | — | 0.812 |
| 5 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.791 |
| 6 | TCGA-NC-A5HT-01A-11R-A26W-07 | — | cohortSQ1 | 0.778 |
| 7 | TCGA-E9-A1N8-01A-11R-A144-07 | — | E | 0.776 |
| 8 | f755bd47-f8ff-4847-9b8e-7d36b7b84155 | — | — | 0.775 |
| 9 | SRR10842373 | — | — | 0.771 |
| 10 | SRR12475144 | — | — | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.411 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.408 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.216 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.166 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.137 | Idelalisib | — uncovered |
| HYPOXIA | 0.108 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.104 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.098 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.085 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.077 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.069 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.049 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.038 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.025 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.013 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.009 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.004 | Inavolisib | — uncovered |